Education
About Us
Working with TipRanks
Follow Us
Merus NV (DE:2GH)
FRANKFURT:2GH
2GH Stock Chart & Stats
Day’s Range― - ―
52-Week Range€29.40 - €58.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$2.64B
Enterprise Value€2.37B
Total Cash (Recent Filing)-$1.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.23
Next Earnings
May 13, 2025EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.05
Shares Outstanding69,090,470
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)90.33
Price to Cash Flow (P/CF)-12.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit65.49
Enterprise Value/Ebitda-8.16
Forecast
1Y Price Target
$78.39Price Target Upside140.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Merus News
See All DE:2GH News
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPetosemtamab is making significant strides in its clinical development, with ongoing Phase 3 trials in both first-line PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma and second/third-line r/m HNSCC.
Efficacy And SafetyPetosemtamab continues to show impressive efficacy and safety in HNSCC indications, now with breakthrough therapy and fast-track designations in both 1L and 2L+ settings.
Market PositionMRUS is well-positioned in the market.
Bears Say
Data InterpretationBCAX's Phase 2 OS remains hard-to-interpret, especially for a post-hoc selection of a small dataset.
Phase 2/3 Program GuidanceBCAX's guidance for its FORTIFI-HN01 Phase 2/3 program triggering its ORR analysis by early 2027 looks aggressive.
Uncertainty In DataThere remains uncertainty regarding the trigger for the primary ORR analysis, which could impact timelines.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.39% Insiders
19.80%
Mutual Funds
0.17% Other Institutional Investors
77.79% Public Companies and
Individual Investors
2GH FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was €29.40 and its highest was €58.50 in the past 12 months.
What is Merus NV’s market cap?
Merus NV’s market cap is $2.64B.
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is May 13, 2025 which is in 16 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Feb 27, 2025. The company reported -€0.422 earnings per share for the quarter, beating the consensus estimate of -€0.783 by €0.361.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -0.94.
How many shares outstanding does Merus NV have?
Merus NV has 69,090,470 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -€0.422 in its last earnings report, beating expectations of -€0.783. Following the earnings report the stock price went up 1.456%.
Which hedge fund is a major shareholder of Merus NV?
Currently, no hedge funds are holding shares in DE:2GH
---
Merus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.39 (140.48% Upside)
$78.39 (140.48% Upside)
Blogger Sentiment
Bullish
DE:2GH Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $194.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.02%
12-Months-Change
Fundamentals
Return on Equity
-42.88%
Trailing 12-Months
Asset Growth
71.24%
Trailing 12-Months
Company Description
Merus NV
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
---
2GH Stock 12 Month Forecast
Average Price Target
€78.39
▲(140.48% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crispr Therapeutics AG
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
Best Analysts Covering 2GH
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+57.72%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +57.72% per trade.
---